DEERFIELD PARTNERS, L.P. - 16 Sep 2022 Form 3 Insider Report for Larimar Therapeutics, Inc. (LRMR)

Role: Director, Dir. by Deputization/10% Group, 10%+ Owner
Signature: /s/ Jonathan Isler, Attorney-in-Fact
Issuer symbol: LRMR
Transactions as of: 16 Sep 2022
Net transactions value: $0
Form type: 3
Filing time: 20 Sep 2022, 20:30:58 UTC
Next filing: 07 Nov 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	LRMR	Common Stock						2,777,777	16 Sep 2022	Direct

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Remarks:

Jonathan Leff, a partner in Deerfield Management Company, L.P., serves as a director of the Issuer. Please see Joint Filer Information Statement attached as Exhibit 99 hereto. Jonathan Isler, Attorney-in-Fact: Power of Attorney, which is hereby incorporated by reference to Exhibit 24 to a Form 3 with regard to Proteon Therapeutics, Inc. filed with the Securities and Exchange Commission on August 4, 2017 by Deerfield Special Situations Fund, L.P., Deerfield Partners, L.P., Deerfield International Master Fund, L.P., Deerfield Private Design Fund III, L.P., Deerfield Private Design Fund IV, L.P., Deerfield Mgmt, L.P., Deerfield Mgmt III, L.P., Deerfield Mgmt IV, L.P., Deerfield Management Company, L.P., and James E. Flynn.